More than 5,000 potentially life-changing treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast reservoir of untapped innovation that could offer hope to millions of patients worldwide. These aren’t merely early-stage concepts; many have undergone substantial preclinical research, toxicology studies, and even early-phase clinical trials, only to be abandoned for reasons often unrelated to their scientific merit or safety profile. The Children’s Tumor Foundation (CTF), a leading non-profit organization, is spearheading an ambitious initiative to unlock this dormant potential, aiming to bridge the critical gap between discarded corporate assets and the urgent medical needs of rare disease communities.
The Unseen Potential: Thousands of Dormant Treatments
The sheer volume of shelved assets, exceeding 5,000 according to CTF CEO Annette Bakker, PhD, underscores a significant inefficiency within the pharmaceutical industry. This phenomenon is a consequence of various commercial and strategic decisions rather than a definitive failure of the drug candidates themselves. Major pharmaceutical companies frequently acquire smaller biotechs for a specific flagship compound, subsequently deprioritizing or shelving other promising assets within the acquired portfolio. Similarly, collaborative partnerships between smaller biotechs and larger pharma entities can dissolve, leaving the smaller company without the necessary resources to continue development. When a biotech firm ceases operations, the invaluable data from its drug candidates often becomes inaccessible, effectively lost to the scientific community and to patients.
These shelved assets represent an extraordinary opportunity. As Dr. Bakker points out, "A shelved asset has already undergone a lot of development, a company has maybe already spent hundreds of millions of dollars on them, and they are now written off as a loss. What if we could take those and put them right into clinical trials? We could win all those years of preclinical and toxicology and go into clinical almost immediately." This approach promises to drastically cut down development timelines and costs, a critical advantage in the notoriously expensive and protracted process of drug discovery.
The Rare Disease Landscape: A Unique Challenge
Understanding the context of rare diseases is crucial to appreciating CTF’s mission. In the United States, a disease is classified as rare if it affects fewer than 200,000 people, as defined by the Orphan Drug Act of 1983. While individually rare, collectively, these conditions affect an estimated 30 million Americans and over 300 million people globally. The vast majority – approximately 95% – of rare diseases currently lack an FDA-approved treatment, leaving patients with limited or no therapeutic options.
Developing drugs for rare diseases presents a unique set of challenges that contribute to the industry’s tendency to shelve promising compounds. The small patient populations make recruiting for clinical trials exceptionally difficult and expensive, often requiring international collaboration and specialized centers. The limited market size can also deter large pharmaceutical companies, which typically prioritize treatments for broader patient populations with higher commercial returns. Furthermore, many rare diseases are poorly understood, lacking robust scientific models or established biomarkers, which complicates research and development. This combination of high R&D costs, scientific complexity, and perceived low commercial viability creates a "valley of death" where many promising early-stage rare disease projects falter and are ultimately abandoned, despite their potential to alleviate suffering.
Children’s Tumor Foundation: A Pioneer in Neurofibromatosis Research
The Children’s Tumor Foundation has a proven track record as a robust drug discovery engine, particularly in the field of neurofibromatosis (NF). NF is a group of complex genetic disorders (including NF1, NF2, and schwannomatosis) that cause tumors to grow on nerves throughout the body, leading to a wide range of symptoms from skin lesions and bone deformities to severe pain, neurological deficits, and life-threatening complications like malignant transformation of tumors. NF1, the most common form, affects approximately 1 in 3,000 people globally, while NF2 and schwannomatosis are even rarer.
CTF’s early-stage funding and strategic investments played a pivotal role in advancing research into MEK inhibitors as a treatment for NF. MEK inhibitors target a specific protein in a cellular signaling pathway (the MAPK pathway) that is often overactive in NF-related tumors, promoting their growth. This foundational work directly led to the development and FDA approval of the first two treatments specifically for NF-related tumors: selumetinib (Koselugo) for inoperable plexiform neurofibromas in NF1, and more recently, other MEK inhibitors showing promise. This success demonstrated CTF’s capability not only to fund research but to strategically guide it from basic science to clinical application, establishing the foundation as a credible and impactful player in rare disease drug development. Building on this success, CTF is now leveraging its expertise and network to tackle the broader problem of shelved assets.
From Pfizer’s Shelf to Patient Success: The Gomekli Paradigm
A compelling example of CTF’s vision in action is the resurrection of Gomekli, a drug initially developed by Pfizer. Gomekli, targeting specific aspects of NF1, had been shelved by the pharmaceutical giant. Dr. Bakker, through persistent advocacy, managed to convince key champions within Pfizer, notably Louis Hall and Laura Sullivan, to license the dormant compound. This critical step led to the establishment of SpringWorks Therapeutics in 2017, a spin-off company specifically created to advance Gomekli and other de-prioritized assets.
The subsequent trajectory of Gomekli was a resounding success. SpringWorks, with focused resources and a dedicated mission, successfully guided the drug through clinical trials. Gomekli received FDA approval in 2023 for its intended indication, offering a new therapeutic option for NF patients. The ultimate validation of this innovative model came shortly after, with SpringWorks Therapeutics being acquired by Merck KGaA for an impressive $3.4 billion. This transaction not only provided a substantial return on investment for the original stakeholders but more importantly, ensured that Gomekli would reach the patients who needed it, under the stewardship of a major pharmaceutical company with the resources to ensure broad access. This success story serves as a powerful proof-of-concept for CTF’s strategy, demonstrating that commercially shelved assets can indeed be rescued, developed, and brought to market, yielding both therapeutic breakthroughs and significant economic value.
Navigating the Hurdles: Patient Recruitment and Data Accessibility
Despite the clear success of the SpringWorks model, scaling this initiative presents considerable challenges. Dr. Bakker notes that while the Gomekli project found champions within Pfizer, "the pharma companies we are calling are not opening the door" for similar collaborations. This reluctance stems from a complex interplay of factors, including intellectual property concerns, resource allocation priorities, and the perceived risks associated with relinquishing control over assets, even those considered non-core.
One of the most formidable hurdles in rare disease drug development, as Dr. Bakker highlights, is patient recruitment. "Everything you do in drug discovery is ten times harder in rare disease," she states. For a condition like NF1, which affects 1 in 3,000 people, the subset of patients with the specific inoperable plexiform tumors targeted by a drug like Gomekli is even smaller. These patients are often geographically dispersed across many countries, making it a slow, costly, and logistically complex endeavor to enroll sufficient numbers for robust clinical trials. This challenge alone can be a significant deterrent for pharmaceutical companies, even for promising compounds.
However, non-profit organizations like CTF possess a unique advantage in this arena. By their very nature, rare disease nonprofits build extensive networks of patients, families, and clinicians who are deeply invested in finding treatments. This inherent network allows CTF to significantly streamline the recruitment process for clinical trials, offering a crucial resource that traditional pharma companies often struggle to replicate.
Beyond patient access, CTF has also established a sophisticated preclinical hub, a constantly expanding network of in vitro and in vivo models, specialized laboratories, and scientific expertise. This hub allows CTF to rigorously evaluate new drug candidates, including shelved assets, through various preclinical stages. Once a pharmaceutical company agrees to license an asset to the foundation, CTF can efficiently guide the drug through further preclinical validation and subsequent clinical trials, leveraging its established infrastructure and scientific acumen. This integrated approach, from patient identification to preclinical validation, is designed to maximize efficiency and accelerate the development pathway for rescued drugs.
Another significant challenge is the inaccessibility of data when biotech companies fail. When a small company goes bankrupt, the research data, toxicology reports, and early clinical findings for its assets often become legally tangled or simply lost, rendering years of scientific effort and millions of dollars effectively worthless. CTF’s model aims to proactively address this by providing a pathway for these assets and their associated data to be transferred and utilized, preventing the complete loss of valuable scientific information.
Building an Ecosystem for Efficiency: CTF’s Vision
CTF’s overarching goal is to transcend individual drug rescue efforts and establish a comprehensive "ecosystem" that systematically identifies, validates, and develops shelved rare disease assets. This ecosystem would be characterized by streamlined processes, collaborative frameworks, and shared resources designed to overcome the inherent difficulties of rare disease drug development.
Key components of this envisioned ecosystem include:
- Centralized Asset Repository: A mechanism for pharmaceutical companies to confidentially submit information about shelved assets, allowing CTF to evaluate their potential for rare disease applications.
- Enhanced Preclinical Hub: Further development of CTF’s existing hub to offer state-of-the-art screening, validation, and pharmacokinetic/pharmacodynamic studies tailored to rare disease biology.
- Global Patient Registries and Networks: Strengthening and expanding patient registries and clinical trial networks to facilitate rapid and efficient patient identification and recruitment for trials.
- Strategic Partnerships: Forging innovative collaboration models with academic institutions, other non-profits, and even smaller biotechs that might be willing to take on development of rescued assets under CTF’s guidance.
- Expert Regulatory Guidance: Leveraging expertise to navigate the complex regulatory pathways for orphan drugs, potentially utilizing accelerated approval mechanisms.
By creating such an ecosystem, CTF believes it can transform the landscape of rare disease drug development. This approach not only promises to rescue individual drugs but to create a sustainable pipeline for bringing new therapies to patients, dramatically reducing the time and cost associated with traditional drug development.
Broader Implications and the Future of Rare Disease Therapeutics
The Children’s Tumor Foundation’s innovative approach to rescuing shelved rare disease drugs carries profound implications that extend beyond neurofibromatosis. Economically, repurposing assets that have already undergone significant initial investment represents a highly cost-effective strategy. It mitigates the financial risks associated with early-stage discovery and preclinical development, which are often the most expensive and failure-prone phases. This efficiency could free up resources for truly novel drug discovery and allow more therapies to reach patients faster.
Ethically, there is a compelling imperative to explore every avenue for treating rare diseases. When promising compounds exist, even if deprioritized by their original developers, their potential to alleviate suffering should not be ignored. CTF’s initiative champions this ethical responsibility, providing a pathway for these compounds to fulfill their therapeutic promise.
The evolving role of non-profit organizations in drug discovery is also highlighted by CTF’s work. Traditionally, non-profits primarily funded academic research. However, organizations like CTF are increasingly becoming active participants in the drug development pipeline, acting as catalysts, incubators, and even de facto drug developers. This shift reflects a growing recognition of their unique ability to mobilize patient communities, attract specialized expertise, and navigate the specific challenges of rare disease research.
Looking ahead, policy considerations will be crucial. Incentives for pharmaceutical companies to share data on shelved assets, perhaps through a structured data repository or liability protections, could greatly accelerate the impact of such initiatives. Regulatory bodies like the FDA could also play a role in facilitating the transfer and expedited review of these de-risked compounds.
The Children’s Tumor Foundation’s courageous endeavor to unlock the hidden potential of shelved rare disease drugs represents a paradigm shift in how we approach therapeutic development for underserved populations. While challenges remain, the successful model of Gomekli and CTF’s commitment to building a comprehensive ecosystem offer a powerful beacon of hope, demonstrating that with strategic vision and collaborative spirit, the thousands of forgotten compounds on pharma shelves can indeed be transformed into life-saving treatments for those who need them most.
